Bioray Biotech Co., Ltd (TPEX: 7561)
Taiwan
· Delayed Price · Currency is TWD
23.00
+0.80 (3.60%)
Jan 3, 2025, 10:37 AM CST
Bioray Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
Net Income | -15.8 | -11.56 | 0.5 | -7.19 | -0.06 | 19.49 | Upgrade
|
Depreciation & Amortization | 25.2 | 24.48 | 21.87 | 18.83 | 15.21 | 15.42 | Upgrade
|
Other Amortization | 0.56 | 0.52 | 0.36 | 0.25 | 0.07 | 0.05 | Upgrade
|
Loss (Gain) From Sale of Assets | -0 | -0.2 | -0.18 | - | 3.06 | 0.35 | Upgrade
|
Asset Writedown & Restructuring Costs | 1.3 | 1.3 | - | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | - | - | - | - | - | -10.08 | Upgrade
|
Stock-Based Compensation | - | - | 0.02 | - | - | - | Upgrade
|
Provision & Write-off of Bad Debts | 0.12 | -0.01 | 0.08 | - | 0.31 | -0.09 | Upgrade
|
Other Operating Activities | -2.08 | -0.27 | 1.8 | 1.62 | -8.21 | -2.72 | Upgrade
|
Change in Accounts Receivable | -9.35 | -0.56 | -5.96 | -13.66 | 7.87 | -11.63 | Upgrade
|
Change in Inventory | 7.37 | -4.12 | -6.44 | 2.82 | -12.62 | -0.41 | Upgrade
|
Change in Accounts Payable | 4.66 | -3.15 | 1.21 | 4.75 | -0.42 | 0.95 | Upgrade
|
Change in Unearned Revenue | -1.05 | -2.52 | -2.98 | 1.49 | -2.34 | 18.62 | Upgrade
|
Change in Other Net Operating Assets | -4.5 | -4.67 | -7.8 | -0.07 | -1.19 | 32.37 | Upgrade
|
Operating Cash Flow | 6.42 | -0.76 | 2.48 | 8.83 | 1.67 | 62.31 | Upgrade
|
Operating Cash Flow Growth | 28.56% | - | -71.93% | 427.42% | -97.31% | 200.02% | Upgrade
|
Capital Expenditures | -2.58 | -10.02 | -59.64 | -14.98 | -51 | -62.76 | Upgrade
|
Sale of Property, Plant & Equipment | 20.56 | 0.2 | 0.36 | 0.55 | 0.08 | 1.24 | Upgrade
|
Cash Acquisitions | - | -3.54 | - | - | - | -31.74 | Upgrade
|
Divestitures | - | - | - | - | - | -22.66 | Upgrade
|
Sale (Purchase) of Intangibles | -0.21 | -0.16 | -0.75 | -0.56 | -0.38 | -0.9 | Upgrade
|
Investment in Securities | - | - | - | - | - | 25.95 | Upgrade
|
Other Investing Activities | 0.53 | 0.97 | 0.39 | -4.8 | -1.6 | -0.38 | Upgrade
|
Investing Cash Flow | 18.31 | -12.55 | -59.63 | -19.79 | -52.9 | -91.27 | Upgrade
|
Short-Term Debt Issued | - | 10 | 15 | 15 | - | 27.2 | Upgrade
|
Total Debt Issued | 45 | 10 | 15 | 15 | - | 27.2 | Upgrade
|
Short-Term Debt Repaid | - | -25 | -25 | -17.2 | - | - | Upgrade
|
Long-Term Debt Repaid | - | -7.59 | -6.42 | -5.95 | -6.08 | -7.23 | Upgrade
|
Total Debt Repaid | -17.82 | -32.59 | -31.42 | -23.15 | -6.08 | -7.23 | Upgrade
|
Net Debt Issued (Repaid) | 27.18 | -22.59 | -16.42 | -8.15 | -6.08 | 19.97 | Upgrade
|
Common Dividends Paid | -6.02 | -6.02 | - | - | -8.02 | -9.75 | Upgrade
|
Other Financing Activities | -0.22 | -0.13 | 86.34 | -0.48 | -1.23 | -9.66 | Upgrade
|
Financing Cash Flow | 14.28 | -28.73 | 69.92 | -8.64 | -15.33 | 0.57 | Upgrade
|
Foreign Exchange Rate Adjustments | 0.01 | 0 | -0.01 | 0.01 | -0.5 | -0.39 | Upgrade
|
Net Cash Flow | 39.02 | -42.04 | 12.75 | -19.59 | -67.05 | -28.78 | Upgrade
|
Free Cash Flow | 3.84 | -10.78 | -57.16 | -6.15 | -49.32 | -0.45 | Upgrade
|
Free Cash Flow Margin | 2.09% | -5.62% | -29.99% | -4.15% | -31.56% | -0.25% | Upgrade
|
Free Cash Flow Per Share | 0.13 | -0.36 | -2.04 | -0.23 | -1.85 | -0.02 | Upgrade
|
Cash Interest Paid | 0.22 | 0.13 | 0.33 | 0.95 | 1.17 | 1.12 | Upgrade
|
Cash Income Tax Paid | 0.23 | 0.03 | -1.17 | 0.36 | 7.99 | 6.06 | Upgrade
|
Levered Free Cash Flow | -31.52 | -12.81 | -60.67 | -5.78 | -54.3 | -40.94 | Upgrade
|
Unlevered Free Cash Flow | -30.66 | -11.98 | -59.81 | -5.18 | -53.57 | -40.24 | Upgrade
|
Change in Net Working Capital | 37.69 | 14.72 | 21.48 | 3.66 | 17.34 | -3.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.